AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21914755 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural steroid group (40 mg triamcinolone acetonide in 29 mL 0.9% saline)
Number of subjects: 133
Study 19052125 — intervention group
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a at a dosage of 90 microg per week for 3.5 years
Number of subjects: 1050
Study 19052125 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 1050
Study 16801668 — intervention group
Group type: EXPERIMENTAL
Intervention: Folate 1 mg/vitamin B(12) 500 microg
Number of subjects: 35
Study 16801668 — intervention group
Group type: EXPERIMENTAL
Intervention: Entacapone
Number of subjects: 35
Study 16801668 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 12925824 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoridated dentifrice
Number of subjects: 11
Study 12925824 — intervention group
Group type: COMPARATOR
Intervention: Non-fluoridated dentifrice
Number of subjects: 11
Study 12925824 — intervention group
Group type: EXPERIMENTAL
Intervention: Human dentine
Number of subjects: 11
Study 12925824 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine dentine
Number of subjects: 11
Study 11061655 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard dose therapy with zidovudine, lamivudine, and indinavir
Number of subjects: 8
Study 9357394 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg seratrodast
Number of subjects: 183
Study 9357394 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 mg seratrodast
Number of subjects: 183
Study 9357394 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 183
Study 8260471 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 g protein/kg per d
Number of subjects: 12
Study 8260471 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 g protein/kg per d
Number of subjects: 12
Study 8260471 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 g protein/kg per d
Number of subjects: 12
Study 8260471 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6 g protein/kg per d
Number of subjects: 12
Study 2877759 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenacetin
Number of subjects: 5
Study 2877759 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol
Number of subjects: 5
Study 2877759 — intervention group
Group type: COMPARATOR
Intervention: Control (water diuresis)
Number of subjects: 5
Study 31626990 — intervention group
Group type: EXPERIMENTAL
Intervention: Reslizumab 3.0 mg/kg every 4 weeks for 52 weeks
Number of subjects: 953
Study 31626990 — intervention group
Group type: EXPERIMENTAL
Intervention: Reslizumab
Number of subjects: 953
Study 29263226 — intervention group
Group type: EXPERIMENTAL
Intervention: Adult definition of silent cerebral infarct (T2-weighted hyperintensity ≥5 mm with corresponding T1-weighted hypointensity on MRI)
Number of subjects: 150
Study 29263226 — intervention group
Group type: COMPARATOR
Intervention: Reference pediatric definition of silent cerebral infarct (T2-weighted hyperintensity ≥3 mm on MRI)
Number of subjects: 150
Study 26860802 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Chinese Medicine (TCM) treatment (herbal injection (Cinobufacini, 20ml/d, d1-d10), herbal decoction (d1-d21), Chinese acupoint application (d1-d21))
Number of subjects: 64
Study 26860802 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Chinese Medicine (TCM) treatment
Number of subjects: 64
Study 26860802 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (pemetrexed (500mg/m(2), d1), docetaxel (75mg/m(2), d1) or gemcitabine (1250mg/m(2), d1 and d8))
Number of subjects: 64
Study 24992975 — intervention group
Group type: EXPERIMENTAL
Intervention: First diagnosis
Number of subjects: 454
Study 24992975 — intervention group
Group type: EXPERIMENTAL
Intervention: Minor discrepancy
Number of subjects: 454
Study 24992975 — intervention group
Group type: EXPERIMENTAL
Intervention: Major discrepancy
Number of subjects: 454
Study 22867511 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialectical Behavior Therapy (DBT)
Number of subjects: 87
Study 22867511 — intervention group
Group type: COMPARATOR
Intervention: General psychiatric management
Number of subjects: 87
Study 20829132 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe (EZM) preparation 1
Number of subjects: 24
Study 20829132 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe (EZM) preparation 2
Number of subjects: 24
Study 20829132 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal standard (omeprazole)
Number of subjects: 24
Study 18937894 — intervention group
Group type: EXPERIMENTAL
Intervention: Soluble dietary fiber (including psyllium, beta-glucan, pectin, and guar gum)
Number of subjects: 0
Study 18937894 — intervention group
Group type: EXPERIMENTAL
Intervention: Soluble fiber from legumes and vegetables
Number of subjects: 0
Study 16866719 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate (mean dose 124.7 mg/d)
Number of subjects: 567
Study 16866719 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate (open-label extension phase only)
Number of subjects: 567
Study 16866719 — intervention group
Group type: COMPARATOR
Intervention: Topiramate (double-blind phase)
Number of subjects: 567
Study 16866719 — intervention group
Group type: COMPARATOR
Intervention: Placebo (double-blind phase)
Number of subjects: 567
Study 16866719 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate (open-label extension phase)
Number of subjects: 567
Study 16866719 — intervention group
Group type: COMPARATOR
Intervention: Placebo (open-label extension phase)
Number of subjects: 567
Study 12811613 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS) - Group T; n=20
Number of subjects: 60
Study 12811613 — intervention group
Group type: EXPERIMENTAL
Intervention: Infrared lasertherapy - Group L; n=20
Number of subjects: 60
Study 12811613 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture - Group A; n=20
Number of subjects: 60
Study 10743866 — intervention group
Group type: EXPERIMENTAL
Intervention: 25% metronidazole gel applied during periodontal surgery
Number of subjects: 43
Study 10743866 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery only
Number of subjects: 43
Study 10743866 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery + 25% metronidazole gel
Number of subjects: 43
Study 10743866 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy untreated sites)
Number of subjects: 43
Study 9184738 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron (1 mg tablets/2 mg dose)
Number of subjects: 24
Study 9184738 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron (8 mg tablets/8 mg dose)
Number of subjects: 24
Study 9184738 — intervention group
Group type: COMPARATOR
Intervention: Prochlorperazine (10 mg tablets/10 mg dose)
Number of subjects: 24
Study 9184738 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 1524898 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast-conserving therapy (BCT) - lumpectomy, axillary clearance, and radiotherapy (50 Gy in 5 weeks external irradiation and a boost with iridium implant of 25 Gy)
Number of subjects: 902
Study 1524898 — intervention group
Group type: COMPARATOR
Intervention: Radical mastectomy (RM)
Number of subjects: 902
Study 1524898 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast-conserving therapy (BCT)
Number of subjects: 902
Study 1524898 — intervention group
Group type: EXPERIMENTAL
Intervention: Salvage treatment for local recurrence
Number of subjects: 902
Study 4050648 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous wave Doppler echocardiography
Number of subjects: 60
Study 31356921 — intervention group
Group type: EXPERIMENTAL
Intervention: ASN002 (20 mg)
Number of subjects: 36
Study 31356921 — intervention group
Group type: EXPERIMENTAL
Intervention: ASN002 (40 mg)
Number of subjects: 36
Study 31356921 — intervention group
Group type: EXPERIMENTAL
Intervention: ASN002 (80 mg)
Number of subjects: 36
Study 31356921 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 29301124 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron-denatured whey protein (Iron-WP) microspheres
Number of subjects: 21
Study 29301124 — intervention group
Group type: COMPARATOR
Intervention: Ferrous sulphate (FeSO4)
Number of subjects: 21
Study 26259770 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramyocardial injection of 100×10(6) autologous bone marrow mononuclear cells
Number of subjects: 23
Study 23329566 — intervention group
Group type: EXPERIMENTAL
Intervention: Health facilities with adequate staffing and availability of medical equipment and medications
Number of subjects: 364
Study 23329566 — intervention group
Group type: EXPERIMENTAL
Intervention: Health facilities performing cesarean sections
Number of subjects: 364
Study 23329566 — intervention group
Group type: EXPERIMENTAL
Intervention: Availability of oxygen in hospitals
Number of subjects: 364
Study 23329566 — intervention group
Group type: EXPERIMENTAL
Intervention: Availability of blood in hospitals
Number of subjects: 364
Study 21521310 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate 35 mg and cholecalciferol 5600 IU (RSD+)
Number of subjects: 164
Study 21521310 — intervention group
Group type: COMPARATOR
Intervention: Risedronate 35 mg alone (RSD)
Number of subjects: 164
Study 21521310 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 164
Study 18645245 — intervention group
Group type: EXPERIMENTAL
Intervention: Q10Vital liquid
Number of subjects: 0
Study 18645245 — intervention group
Group type: EXPERIMENTAL
Intervention: Q10Vital powder
Number of subjects: 0
Study 18645245 — intervention group
Group type: COMPARATOR
Intervention: Soft-gel capsules with CoQ10 in soybean oil (reference)
Number of subjects: 0
Study 16155071 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual misoprostol (600 microg every 3 h for a maximum of three doses)
Number of subjects: 180
Study 16155071 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended course of sublingual misoprostol (400 microg daily for 1 week)
Number of subjects: 180
Study 16155071 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended course of sublingual misoprostol
Number of subjects: 180
Study 12972485 — intervention group
Group type: EXPERIMENTAL
Intervention: Postinjection immobilisation in elastic wrist orthoses (n=58)
Number of subjects: 117
Study 12972485 — intervention group
Group type: COMPARATOR
Intervention: Normal postinjection activity (n=59)
Number of subjects: 117
Study 11219162 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (100,000 IU)
Number of subjects: 300
Study 11219162 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study 11219162 — intervention group
Group type: EXPERIMENTAL
Intervention: Measles vaccine
Number of subjects: 300
Study 11219162 — intervention group
Group type: EXPERIMENTAL
Intervention: Poliomyelitis vaccine
Number of subjects: 300
Study 11219162 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation and measles vaccine interaction
Number of subjects: 300
Study 8808520 — intervention group
Group type: EXPERIMENTAL
Intervention: KCl (7 mEq in 200 mL of 0.9% NaCl)
Number of subjects: 12
Study 8808520 — intervention group
Group type: EXPERIMENTAL
Intervention: MgSO4 (10 mL 20% in 200 mL of 0.9% NaCl)
Number of subjects: 12
Study 8808520 — intervention group
Group type: EXPERIMENTAL
Intervention: Procainamide (maximal dose, 10 mg/kg of body weight over a 5‐minute period)
Number of subjects: 12
Study 8808520 — intervention group
Group type: COMPARATOR
Intervention: NaCl (0.9%, 200 mL)
Number of subjects: 12
Study 1329220 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination carboplatin/etoposide/vincristine (CEV)
Number of subjects: 0
Study 1329220 — intervention group
Group type: COMPARATOR
Intervention: Etoposide/vincristine (control)
Number of subjects: 0
Study 4057572 — intervention group
Group type: EXPERIMENTAL
Intervention: PAV therapy in stage IV cases
Number of subjects: 0
Study 4057572 — intervention group
Group type: EXPERIMENTAL
Intervention: PAV therapy in operable cases
Number of subjects: 0
Study 4057572 — intervention group
Group type: COMPARATOR
Intervention: Bestatin treatment in stage Ib and II cases
Number of subjects: 0
Study 4057572 — intervention group
Group type: EXPERIMENTAL
Intervention: PPSM treatment with prophylactic lymph node dissection
Number of subjects: 0
Study 4057572 — intervention group
Group type: COMPARATOR
Intervention: PPSM treatment without prophylactic lymph node dissection
Number of subjects: 0
Study 30366505 — intervention group
Group type: COMPARATOR
Intervention: Filtered Back Projection (FBP) with 120 kV and 300 mA (Group A)
Number of subjects: 90
Study 30366505 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive Iterative Dose Reduction 3D (AIDR3D) with 80 kV and auto mA (Group B)
Number of subjects: 90
Study 29366667 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional approach (TA)
Number of subjects: 18
Study 29366667 — intervention group
Group type: EXPERIMENTAL
Intervention: Perpendicular approach (PA)
Number of subjects: 18
Study 29366667 — intervention group
Group type: EXPERIMENTAL
Intervention: Axillary approach (AA)
Number of subjects: 18
Study 27162030 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary vein antrum isolation
Number of subjects: 513
Study 24731889 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteopathic sham therapy
Number of subjects: 206
Study 24731889 — intervention group
Group type: COMPARATOR
Intervention: Routine pediatric care (Control)
Number of subjects: 206
Study 22613238 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesio Taping
Number of subjects: 60
Study 22613238 — intervention group
Group type: COMPARATOR
Intervention: Sham Taping
Number of subjects: 60
Study 20853611 — intervention group
Group type: EXPERIMENTAL
Intervention: V1 - bortezomib 1.3 mg/m2 intravenously on days 1, 4, 8, and 11 of a 21-day cycle
Number of subjects: 101
Study 20853611 — intervention group
Group type: EXPERIMENTAL
Intervention: V2 - bortezomib 1.3 mg/m2 intravenously on days 1, 4, 8, and 11, melphalan 20 mg orally on day 2 of a 28-day cycle
Number of subjects: 101
Study 17204317 — intervention group
Group type: EXPERIMENTAL
Intervention: HFA‐BDP (400 microg/d)
Number of subjects: 58
Study 17204317 — intervention group
Group type: COMPARATOR
Intervention: FP (500 microg/d)
Number of subjects: 58
Study 15123761 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity strength training (HI; n = 8)
Number of subjects: 22
Study 15123761 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-moderate intensity strength training (LI; n = 6)
Number of subjects: 22
Study 15123761 — intervention group
Group type: COMPARATOR
Intervention: Weight-free placebo-control training (PC; n = 8)
Number of subjects: 22
Study 12165364 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation (rTMS)
Number of subjects: 17
Study 9717679 — intervention group
Group type: EXPERIMENTAL
Intervention: Priorix lot 1
Number of subjects: 255
Study 9717679 — intervention group
Group type: EXPERIMENTAL
Intervention: Priorix lot 2
Number of subjects: 255
Study 9717679 — intervention group
Group type: COMPARATOR
Intervention: M-M-R II
Number of subjects: 255
Study 9306483 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-1 infected children
Number of subjects: 458
Study 9306483 — intervention group
Group type: COMPARATOR
Intervention: Seroreverter infants
Number of subjects: 458
Study 9306483 — intervention group
Group type: COMPARATOR
Intervention: Control infants
Number of subjects: 458
Study 9306483 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine use
Number of subjects: 458
Study 1959461 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin (alpha-adrenergic blocker)
Number of subjects: 51
Study 1959461 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 7238141 — intervention group
Group type: EXPERIMENTAL
Intervention: Skill training
Number of subjects: 36
Study 7238141 — intervention group
Group type: COMPARATOR
Intervention: Attention control
Number of subjects: 36
Study 7238141 — intervention group
Group type: COMPARATOR
Intervention: Nontreatment control
Number of subjects: 36
Study 30777846 — intervention group
Group type: EXPERIMENTAL
Intervention: RAW Mindfulness Program (6 sessions)
Number of subjects: 143
Study 30777846 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 143
Study 30777846 — intervention group
Group type: EXPERIMENTAL
Intervention: RAW Mindfulness Program (5 to 6 sessions completed)
Number of subjects: 143
Study 28035659 — intervention group
Group type: EXPERIMENTAL
Intervention: Patch testing for food additives
Number of subjects: 24
Study 23568405 — intervention group
Group type: EXPERIMENTAL
Intervention: Newsletter with comprehensive health risk information insert
Number of subjects: 0
Study 23568405 — intervention group
Group type: COMPARATOR
Intervention: Newsletter with brief health risk information
Number of subjects: 0
Study 23568405 — intervention group
Group type: EXPERIMENTAL
Intervention: Discussion of breast cancer risk with physician
Number of subjects: 0
Study 23568405 — intervention group
Group type: EXPERIMENTAL
Intervention: Discussion of heart disease risk with physician
Number of subjects: 0
Study 23568405 — intervention group
Group type: EXPERIMENTAL
Intervention: Discussion of osteoporosis risk with physician
Number of subjects: 0
Study 21187207 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot and ankle strength measures (hallux plantar flexion strength)
Number of subjects: 305
Study 21187207 — intervention group
Group type: EXPERIMENTAL
Intervention: Ankle inversion-eversion range of motion
Number of subjects: 305
Study 21187207 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical measures of foot and ankle strength, range of motion, posture, and deformity
Number of subjects: 305
Study 19920724 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-frequency pulsed electromagnetic field (PEMF) therapy
Number of subjects: 56
Study 19920724 — intervention group
Group type: COMPARATOR
Intervention: Sham therapy
Number of subjects: 56
Study 17310933 — intervention group
Group type: EXPERIMENTAL
Intervention: Monosegmental balloon kyphoplasty
Number of subjects: 60
Study 17310933 — intervention group
Group type: COMPARATOR
Intervention: Adjacent prophylactic balloon kyphoplasty
Number of subjects: 60
Study 14603267 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 0.4 mg/kg
Number of subjects: 54
Study 14603267 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 0.8 mg/kg
Number of subjects: 54
Study 14603267 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine
Number of subjects: 54
Study 11292931 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent cold blood cardioplegia (Group 1)
Number of subjects: 90
Study 11292931 — intervention group
Group type: EXPERIMENTAL
Intervention: Terminal warm cardioplegia and controlled reperfusion (Group 2)
Number of subjects: 90
Study 11292931 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning (Group 3)
Number of subjects: 90
Study 9034275 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic ranitidine treatment for 4 days
Number of subjects: 53
Study 9034275 — intervention group
Group type: COMPARATOR
Intervention: Control group (no ranitidine treatment)
Number of subjects: 53
Study 9034275 — intervention group
Group type: EXPERIMENTAL
Intervention: Surfactant treatment for infant respiratory distress syndrome
Number of subjects: 53
Study 8498463 — intervention group
Group type: EXPERIMENTAL
Intervention: Choice of which of five ceramic objects to paint
Number of subjects: 22
Study 8498463 — intervention group
Group type: COMPARATOR
Intervention: No choice of ceramic object to paint (control)
Number of subjects: 22
Study 3538477 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminophylline calculated without knowledge of admission serum theophylline concentration (Group A)
Number of subjects: 50
Study 3538477 — intervention group
Group type: COMPARATOR
Intervention: Aminophylline calculated with knowledge of admission serum theophylline concentration (Group B)
Number of subjects: 50
Study 30340715 — intervention group
Group type: EXPERIMENTAL
Intervention: Online fundus photograph program
Number of subjects: 46
Study 30340715 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 46
Study 27033352 — intervention group
Group type: EXPERIMENTAL
Intervention: IQ·SPECT with half the standard injected activity (462.5-550 MBq)
Number of subjects: 93
Study 27033352 — intervention group
Group type: COMPARATOR
Intervention: LEHR collimators with full injected activity (925-1100 MBq)
Number of subjects: 93
Study 24885949 — intervention group
Group type: EXPERIMENTAL
Intervention: Hombre Seguro sexual risk reduction intervention
Number of subjects: 400
Study 24885949 — intervention group
Group type: COMPARATOR
Intervention: Time-attention didactic control condition
Number of subjects: 400
Study 22230963 — intervention group
Group type: EXPERIMENTAL
Intervention: FOCUS Shear (F)
Number of subjects: 182
Study 22230963 — intervention group
Group type: COMPARATOR
Intervention: LigaSure LF1212 (L)
Number of subjects: 182
Study 20378080 — intervention group
Group type: EXPERIMENTAL
Intervention: Mipomersen 100 mg/week and higher
Number of subjects: 74
Study 20378080 — intervention group
Group type: EXPERIMENTAL
Intervention: Mipomersen 200 mg/week
Number of subjects: 74
Study 20378080 — intervention group
Group type: EXPERIMENTAL
Intervention: Mipomersen
Number of subjects: 74
Study 20378080 — intervention group
Group type: EXPERIMENTAL
Intervention: Mipomersen 200 mg/week (13-week cohort)
Number of subjects: 74
Study 19142279 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse led model of care for chronic conditions
Number of subjects: 0
Study 15791113 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous acetaminophen (1 g)
Number of subjects: 151
Study 15791113 — intervention group
Group type: EXPERIMENTAL
Intervention: Propacetamol (2 g)
Number of subjects: 151
Study 15791113 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 151
Study 12422025 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Exercise (PE)
Number of subjects: 860
Study 12422025 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress Management Training (SMT)
Number of subjects: 860
Study 12422025 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated Health Programme (IHP)
Number of subjects: 860
Study 12422025 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 860
Study 10091913 — intervention group
Group type: EXPERIMENTAL
Intervention: Three‐period crossover design
Number of subjects: 0
Study 10091913 — intervention group
Group type: EXPERIMENTAL
Intervention: Model without carryover effects
Number of subjects: 0